BRIEF published on 10/15/2024 at 07:35, 1 year 5 months ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 5 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 5 months ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 09/20/2024 at 09:07, 1 year 6 months ago Rapport Financier Semestriel 2024
BRIEF published on 09/04/2024 at 07:35, 1 year 6 months ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
BRIEF published on 09/04/2024 at 07:35, 1 year 6 months ago MaaT Pharma annonce sa participation à des conférences investisseurs et médicales en septembre Investisseurs Conférence Médicale Thérapies MET Transplantation Cellulaire Cancers
PRESS RELEASE published on 09/04/2024 at 07:30, 1 year 6 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce sa participation aux conférences investisseurs et médicales en septembre, avec des présentations lors du Congrès annuel de la Society of Hematologic Oncology à Houston et à d'autres événements internationaux Conférences Investisseurs Microbiote MaaT Pharma Cancers
BRIEF published on 05/15/2024 at 07:35, 1 year 10 months ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
BRIEF published on 05/15/2024 at 07:35, 1 year 10 months ago MaaT Pharma clôture avec succès une levée de fonds de 19,2 millions d'euros Investissement Biotechnologie Essais Cliniques Levée De Fonds MaaT Pharma
PRESS RELEASE published on 05/15/2024 at 07:30, 1 year 10 months ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
Published on 03/20/2026 at 13:30, 2 days 8 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 9 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 9 hours 42 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 23 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 1 hour ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 1 hour ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 3 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 3 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
